UniQuest congratulates ResApp Health Limited (ASX:RAP) following the company’s
announcement today that it is planning a clinical study at Massachusetts General Hospital (MGH)
a 1,000-bed academic medical centre in Boston (US).

ResApp is developing a smartphone medical application for the diagnosis and management of
respiratory disease.

The company, established in 2014 to commercialise technology developed by The University of
Queensland (UQ)’s Associate Professor Udantha Abyratne, will conduct a clinical study with MGH
for the ResAppDx US paediatric study to support its FDA de novo submission.

UniQuest CEO Dr Dean Moss said he was delighted to see the association of such a prestigious
institution with the development of the technology.

“MGH’s involvement is testament to the quality of UQ’s research in this area and the excellent
progress ResApp has made in bringing this exciting discovery closer to market,” Dr Moss said. 

UniQuest Communications: Nicole Cowan,, Tel. +61 409 767 199